Dexcom Stock

Dexcom Net Income

The Net Income of Dexcom (DXCM) as of Aug 17, 2026 is 836.30 M USD. In the previous year, Net Income was 576.20 M USD — a change of 45.14% (higher).

Net Income

836.30 MUSD

YoY

45.14%

Last updated:

In 2026, Dexcom's profit amounted to 836.30 M USD, a 45.14% increase from the 576.20 M USD profit recorded in the previous year.

The Dexcom Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

NET INCOME (B USD)
Date
NET INCOME (B USD)
Jan 1, 2023
0.54 base
Jan 1, 2024
0.58 base
Jan 1, 2025
0.84 base
Jan 1, 2026 (e)
1.04 base
Jan 1, 2027 (e)
1.22 base
Jan 1, 2028 (e)
1.44 base
Jan 1, 2029 (e)
1.66 base
Jan 1, 2030 (e)
1.94 base
YEARNET INCOME (B USD)
2030 est 1.94
2029 est 1.66
2028 est 1.44
2027 est 1.22
2026 est 1.04
2025 0.84
2024 0.58
2023 0.54
2022 0.34
2021 0.22
2020 0.49
2019 0.10
2018 -0.13
2017 -0.05
2016 -0.07
2015 -0.06
2014 -0.02
2013 -0.03
2012 -0.05
2011 -0.04
2010 -0.06
2009 -0.05
2008 -0.06
2007 -0.05
2006 -0.05
Access this data via the Eulerpool API

Dexcom Revenue

Dexcom Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
3.62 B USD
597.70 M USD
541.50 M USD
Jan 1, 2024
4.03 B USD
600.00 M USD
576.20 M USD
Jan 1, 2025
4.66 B USD
911.80 M USD
836.30 M USD
Jan 1, 2026 (e)
5.23 B USD
1.88 B USD
1.04 B USD
Jan 1, 2027 (e)
5.80 B USD
2.10 B USD
1.22 B USD
Jan 1, 2028 (e)
6.51 B USD
2.35 B USD
1.44 B USD
Jan 1, 2029 (e)
7.21 B USD
2.60 B USD
1.66 B USD
Jan 1, 2030 (e)
8.04 B USD
2.89 B USD
1.94 B USD

Dexcom Margins

Dexcom stock margins

The Dexcom margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dexcom. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dexcom.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
63.19 %
16.50 %
14.95 %
Jan 1, 2024
60.46 %
14.88 %
14.29 %
Jan 1, 2025
60.10 %
19.56 %
17.94 %
Jan 1, 2026 (e)
60.10 %
35.96 %
19.85 %
Jan 1, 2027 (e)
60.10 %
36.13 %
21.01 %
Jan 1, 2028 (e)
60.10 %
36.00 %
22.10 %
Jan 1, 2029 (e)
60.10 %
36.00 %
22.97 %
Jan 1, 2030 (e)
60.10 %
36.00 %
24.18 %

Dexcom Stock analysis

What does Dexcom do? Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Dexcom's Profit Margins

The profit margins of Dexcom represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Dexcom's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Dexcom's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Dexcom's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Dexcom’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Dexcom stock

Net Income of Dexcom is 836.30 M USD in 2026.

Net Income of Dexcom changed from 576.20 M USD to 836.30 M USD, representing a 45.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Income Dexcom since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Dexcom historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

Income Statement — Dexcom

All Key Metrics — Dexcom